Side effects from a high-dose clozapine treatment for a schizophrenic patient led to massive compliance problems. The dose of clozapine could be halved without recurrence of an acute psychotic symptomatology by concomitantly administering amisulpride. The side effects, especially hypersalivation, disappeared almost entirely, which in turn led to good compliance. In a short review we would like to present the pathophysiology and therapeutic options of clozapine-induced hypersalivation.
References
-
1
Alvir J M, Lieberman J A, Safferman A Z, Schwimmer J L, Schaaf J A.
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
N Engl J Med.
1993;
329
162-167
-
2
Ben Aryeh H, Jungerman T, Szargel R, Klein E, Laufer D.
Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data.
Biol Psychiatry.
1996;
39
946-949
-
3
Copp P J, Lament R, Tennent T G.
Amitriptyline in clozapine-induced sialorrhoea.
Br J Psychiatry.
1991;
159
166
-
4
Fritze J, Elliger T.
Pirenzepine for clozapine-induced hypersalivation.
Lancet.
1995;
346
1034
-
5
Schmauss M, Wolff R, Erfurth A, Ruther E.
Tolerability of long term clozapine treatment.
Psychopharmacology (Berl).
1989;
99 (Suppl)
S105-108
-
6
Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J.
Reduction of clozapine-induced hypersalivation by pirenzepine is safe.
Pharmacopsychiatry.
2004;
37
43-45
-
7
Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A.
Trihexyphenidyl treatment of clozapine-induced hypersalivation.
Int Clin Psychopharmacol.
1997;
12
213-215
-
8
Szabadi E.
Clozapine-induced hypersalivation and the alpha-2 adrenoceptor.
Br J Psychiatry.
1996;
169
380-381
-
9
Szabadi E.
Clozapine-induced hypersalivation.
Br J Psychiatry.
1997;
171
89
-
10
Zink M, Knopf U, Henn F A, Thome J.
Combination of clozapine and amisulpride in treatment-resistant schizophrenia case reports and review of the literature.
Pharmacopsychiatry..
2004;
37
26-31
Dr. Bernhard Croissant, MD
Department of Addictive Behavior and Addiction Medicine
Central Institute of Mental Health
University of Heidelberg
J 5
68159 Mannheim
Phone: +49 621 1703 3502
Fax: +49 621 1703 1205
Email: croissant@zi-mannheim.de
